Clinical trials: Anlotinib
Non-small Cell Lung Cancer, Minimal Residual Disease
Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation
To study the efficacy of sintilimab combined with anlotinib for perioperative non-small cell lung cancer. To explore the clearance effect of sintilimab combined with anlotinib for postoperative adjuvant therapy based on…
- Conditions
- Non-small Cell Lung Cancer, Minimal Residual Disease, Immunotherapy, Anti-angiogenesis
- Trial name
- NCT05460195
- Testing
- sintilimab combined with anlotinib, sintilimab monotherapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shanghai Chest Hospital
Small Cell Lung Cancer (SCLC)
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
SCLC has short doubling time, high proliferation rate and early widespread metastasis. Most patients with SCLC have hematogenous metastasis. SCLC is highly sensitive to initial chemoradiotherapy, but the recurrence rate is high.
- Trial name
- NCT05027100
- Testing
- Anlotinib Tislelizumab Irinotecan
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Haibo Zhang
Effect of Drugs, Quality of Life
Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma
For local relapse not amenable to reasonable curative surgery or for those with metastatic chordoma, chemotherapy is recognised as inactive.
- Conditions
- Effect of Drugs, Quality of Life, Chordoma, Advanced Cancer
- Trial name
- CSSG-03 (NCT04042597)
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
Soft Tissue Sarcoma
A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma
A multicenter, randomized, double-blind, parallel-controlled Phase III trial to evaluate the efficacy and safety of anotinib hydrochloride capsule combined with epirubicin hydrochloride versus placebo combined with epirubicin…
- Trial name
- NCT05121350
- Testing
- Anlotinib hydrochloride capsule, Epirubicin
- Where
- 3 sites in China
- Volunteers
- 256 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Melanoma
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
The purpose of this study is to evaluate the efficacy and safety of recombinant human interferon-α1b (IFN-α1b) combined with toripalimab and anlotinib hydrochloride in patients with unresectable advanced melanoma.
- Trial name
- NCT05539118
- Testing
- Recombinant human interferon α1b, Toripalimab, Anlotinib hydrochloride
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Xijing Hospital
Esophageal Squamous Cell Carcinoma
Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
To compare the effects and safety of Anlotinib with placebo in patients with esophageal squamous cell carcinoma(ESCC).
- Trial name
- NCT02649361
- Testing
- Anlotinib
- Where
- 18 sites in China
- Volunteers
- 164 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer
This study aims to observe and explore the efficacy and safety of Anlotinib combined with penpulimab in the treatment of radioiodine refractory differentiated thyroid cancer with first-line resistance to angiogenesis inhibitors…
- Trial name
- NCT06062563
- Testing
- Anlotinib Hydrochloride Capsule and Penpulimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking Union Medical College Hospital
Triple Negative Breast Cancer
The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC
The purpose of this study is to evaluate the efficacy and safety of Sintilimab plus anlotinib combined with chemotherapy as neoadjuvant therapy in participants who have triple negative breast cancer (TNBC).
- Trial name
- NeoSACT (NCT04877821)
- Testing
- Sintilimab, Anlotinib, Nab paclitaxel
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Guangdong Provincial People's Hospital
Sarcoma
Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children
The purpose is to observe and evaluate the safety and effectiveness of anlotinib in children with progressive, recurrent, and refractory sarcoma. Pharmacokinetics was also detected.
- Trial name
- NCT04659733
- Testing
- Anlotinib hydrochloride
- Volunteers
- 36 people
- Sponsor
- Yizhuo Zhang
Advanced Lung Carcinoma
A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
This is an open, multi-cohort, exploratory phase II study on the safety and efficacy of TQB3616 combined with Anlotinib hydrochloride capsules or standard chemotherapy in the treatment of advanced lung cancer.
- Trial name
- NCT04924192
- Testing
- TQB3616 capsules, Anlotinib Hydrochloride capsules, Irinotecan Hydrochloride for Injection
- Where
- 7 sites in China
- Volunteers
- 21 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Lung Cancer, Advanced Stage
First-line Combination Treatment Based on Anlotinib
The aim of this study is to explore safety and therapeutic efficacy of anlotinib combined with erlotinib/chemotherapy/IBI308 as first-line treatment in advanced NSCLC patients.
- Trial name
- NCT03628521
- Testing
- Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shanghai Chest Hospital
Hepatocellular Carcinoma
Adjuvant Therapy With Anlotinib for HCC
Patients with high risk of disease recurrence after curative resection for hepatocellular carcinoma (HCC) deserve active intervention. However, there's limited treatment choice for these patients.
- Trial name
- NCT04947371
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Sponsor
- Shanghai Zhongshan Hospital
Small Cell Lung Carcinoma
First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC
Our aim in this study was to evaluate the efficacy and safety of etoposide combined with cisplatin or carboplatin (EC/EP) chemotherapy regimens followed by toripalimab combined with anlotinib for maintenance in extensive small…
- Trial name
- NCT04363255
- Testing
- Etoposide Injection, Carboplatin Injection, Cisplatin injection
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Taizhou Hospital
Cervical Cancer
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
The goal of this clinical trial is to test a new treatment combination including cadonilimab, anlotinib and granulocyte-macrophage colony-stimulating factor (GM-CSF) in recurrent, metastasis and persistent cervical cancer.
- Trial name
- NCT05817214
- Testing
- Cadonilimab, Anlotinib, Granulocyte-Macrophage Colony-Stimulating Factor
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Zhongnan Hospital
Soft Tissue Sarcoma, Doxorubicin
Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
Exploring the Efficacy and Safety of Anlotinib Combined with Doxorubicin Monotherapy and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
- Conditions
- Soft Tissue Sarcoma, Doxorubicin, Radiotherapy
- Trial name
- NCT06506838
- Testing
- Anlotinib
- Where
- 2 sites in China
- Volunteers
- 39 people
- Sponsor
- Guangdong Provincial People's Hospital
Extensive Stage Small Cell Lung Cancer
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
This is a randomized, controlled, open-label, multicenter clinical study to evaluate the efficacy and safety of carboplatin/cisplatin + etoposide + benmelstobart sequential benmelstobart combined with anlotinib versus…
- Trial name
- NCT06897579
- Testing
- Carboplatin for injection/cisplatin for injection + etoposide injection + benmelstobart injection + Anlotinib hydrochloride capsule, Carboplatin for injection/Cisplatin for injection + etoposide injection + Tislelizumab injection
- Where
- 32 sites in China
- Volunteers
- 40 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastric Cancer
An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC
1. Main objective: to evaluate the pathological complete response (pCR) of gastric cancer after local advanced COVID-19 infection by two kinds of immunotherapy combined with Anlotinib Hydrochloride Capsules and neoadjuvant…
- Trial name
- NCT05800080
- Testing
- Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy;Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Xijing Hospital
Sarcoma, Soft Tissue
Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients
Anlotinib is a multi-target receptor tyrosine kinase inhibitor. It can inhibit the angiogenesis related kinase, such as Vascular Endothelial Growth Factor Receptor (VEGFR), Fibroblast Growth Factor Receptor(FGFR)…
- Trial name
- ALTER-S005 (NCT03815474)
- Testing
- anlotinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Non-squamous Non-small Cell Lung Cancer
Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel
The purpose of this clinical study is to evaluate the tolerability and toxicity of different dose of Anlotinib puls Pemetrexed/Docetaxel in Second-line Treatment of Advanced Gene Negative Non-squamous Non-small Cell Lung Cancer …
- Trial name
- NCT03566576
- Testing
- Anlotinib, Pemetrexed, Docetaxel
- Volunteers
- 18 people
- Sponsor
- Fujian Cancer Hospital
Soft Tissue Sarcoma (STS)
Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma
Soft tissue sarcoma is a rare cancer that often requires surgery combined with radiotherapy. Preoperative radiotherapy can improve the chance of complete tumor removal and limb preservation, but some patients still experience…
- Trial name
- SPARE-04 (NCT07612098)
- Testing
- Anlotinib, Penpulimab, Preoperative Radiotherapy
- Where
- China
- Volunteers
- 274 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences